CN1256950C - 海狗油软胶囊在制备调节血脂保健品中的应用 - Google Patents
海狗油软胶囊在制备调节血脂保健品中的应用 Download PDFInfo
- Publication number
- CN1256950C CN1256950C CNB031007546A CN03100754A CN1256950C CN 1256950 C CN1256950 C CN 1256950C CN B031007546 A CNB031007546 A CN B031007546A CN 03100754 A CN03100754 A CN 03100754A CN 1256950 C CN1256950 C CN 1256950C
- Authority
- CN
- China
- Prior art keywords
- soft capsule
- test
- group
- dosage
- phocae vitulinae
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000007901 soft capsule Substances 0.000 title claims abstract description 43
- 210000004369 blood Anatomy 0.000 title claims abstract description 28
- 239000008280 blood Substances 0.000 title claims abstract description 28
- 230000036541 health Effects 0.000 title claims abstract description 9
- 230000001105 regulatory effect Effects 0.000 title abstract 3
- 235000019165 vitamin E Nutrition 0.000 claims abstract description 11
- 239000011709 vitamin E Substances 0.000 claims abstract description 11
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 20
- 150000002632 lipids Chemical class 0.000 claims description 17
- 230000033228 biological regulation Effects 0.000 claims description 14
- 229930003427 Vitamin E Natural products 0.000 claims description 10
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 10
- 229940046009 vitamin E Drugs 0.000 claims description 10
- 238000002360 preparation method Methods 0.000 claims description 6
- 239000004615 ingredient Substances 0.000 claims 1
- 235000021323 fish oil Nutrition 0.000 abstract description 10
- 239000000203 mixture Substances 0.000 abstract description 2
- 238000012360 testing method Methods 0.000 description 53
- 241000700159 Rattus Species 0.000 description 34
- 241001465754 Metazoa Species 0.000 description 32
- 230000037396 body weight Effects 0.000 description 28
- 235000019197 fats Nutrition 0.000 description 24
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 23
- 210000002784 stomach Anatomy 0.000 description 16
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 description 15
- DVSZKTAMJJTWFG-UHFFFAOYSA-N docosa-2,4,6,8,10,12-hexaenoic acid Chemical compound CCCCCCCCCC=CC=CC=CC=CC=CC=CC(O)=O DVSZKTAMJJTWFG-UHFFFAOYSA-N 0.000 description 15
- MBMBGCFOFBJSGT-KUBAVDMBSA-N docosahexaenoic acid Natural products CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 15
- 235000020673 eicosapentaenoic acid Nutrition 0.000 description 15
- 229960005135 eicosapentaenoic acid Drugs 0.000 description 15
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 description 15
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 15
- 239000002904 solvent Substances 0.000 description 14
- 241000283216 Phocidae Species 0.000 description 13
- PIFPCDRPHCQLSJ-WYIJOVFWSA-N 4,8,12,15,19-Docosapentaenoic acid Chemical compound CC\C=C\CC\C=C\C\C=C\CC\C=C\CC\C=C\CCC(O)=O PIFPCDRPHCQLSJ-WYIJOVFWSA-N 0.000 description 11
- 238000010171 animal model Methods 0.000 description 10
- 235000012000 cholesterol Nutrition 0.000 description 10
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 10
- 241000699670 Mus sp. Species 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 239000013642 negative control Substances 0.000 description 9
- PIFPCDRPHCQLSJ-UHFFFAOYSA-N Clupanodonic acid Natural products CCC=CCCC=CCC=CCCC=CCCC=CCCC(O)=O PIFPCDRPHCQLSJ-UHFFFAOYSA-N 0.000 description 8
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 8
- 235000021290 n-3 DPA Nutrition 0.000 description 8
- 210000002966 serum Anatomy 0.000 description 8
- 210000003743 erythrocyte Anatomy 0.000 description 7
- 235000013305 food Nutrition 0.000 description 7
- 150000002333 glycines Chemical class 0.000 description 7
- YUFFSWGQGVEMMI-UHFFFAOYSA-N (7Z,10Z,13Z,16Z,19Z)-7,10,13,16,19-docosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCCCC(O)=O YUFFSWGQGVEMMI-UHFFFAOYSA-N 0.000 description 6
- YUFFSWGQGVEMMI-JLNKQSITSA-N (7Z,10Z,13Z,16Z,19Z)-docosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCCCC(O)=O YUFFSWGQGVEMMI-JLNKQSITSA-N 0.000 description 6
- 241000282472 Canis lupus familiaris Species 0.000 description 6
- 102000015779 HDL Lipoproteins Human genes 0.000 description 6
- 108010010234 HDL Lipoproteins Proteins 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 244000052616 bacterial pathogen Species 0.000 description 6
- XIVFQYWMMJWUCD-UHFFFAOYSA-N dihydrophaseic acid Natural products C1C(O)CC2(C)OCC1(C)C2(O)C=CC(C)=CC(O)=O XIVFQYWMMJWUCD-UHFFFAOYSA-N 0.000 description 6
- 150000002978 peroxides Chemical class 0.000 description 6
- 239000013641 positive control Substances 0.000 description 6
- 102000001554 Hemoglobins Human genes 0.000 description 5
- 108010054147 Hemoglobins Proteins 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 101710098398 Probable alanine aminotransferase, mitochondrial Proteins 0.000 description 5
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 5
- 229910052785 arsenic Inorganic materials 0.000 description 5
- RQNWIZPPADIBDY-UHFFFAOYSA-N arsenic atom Chemical compound [As] RQNWIZPPADIBDY-UHFFFAOYSA-N 0.000 description 5
- 229940109239 creatinine Drugs 0.000 description 5
- 239000008103 glucose Substances 0.000 description 5
- 210000000265 leukocyte Anatomy 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 5
- 102000009027 Albumins Human genes 0.000 description 4
- 108010088751 Albumins Proteins 0.000 description 4
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 229960004397 cyclophosphamide Drugs 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- 238000013112 stability test Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 201000001320 Atherosclerosis Diseases 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 208000005374 Poisoning Diseases 0.000 description 3
- 241000700157 Rattus norvegicus Species 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 208000029078 coronary artery disease Diseases 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 210000001198 duodenum Anatomy 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 239000012535 impurity Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 231100000572 poisoning Toxicity 0.000 description 3
- 230000000607 poisoning effect Effects 0.000 description 3
- 238000004321 preservation Methods 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 241000251468 Actinopterygii Species 0.000 description 2
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 2
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 102000007330 LDL Lipoproteins Human genes 0.000 description 2
- 108010007622 LDL Lipoproteins Proteins 0.000 description 2
- 241000269799 Perca fluviatilis Species 0.000 description 2
- 241000607142 Salmonella Species 0.000 description 2
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 2
- 238000011047 acute toxicity test Methods 0.000 description 2
- 238000009534 blood test Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 238000004043 dyeing Methods 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 230000002489 hematologic effect Effects 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 230000008676 import Effects 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 230000002906 microbiologic effect Effects 0.000 description 2
- 230000000050 nutritive effect Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 231100000915 pathological change Toxicity 0.000 description 2
- 230000036285 pathological change Effects 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 150000003071 polychlorinated biphenyls Chemical class 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 210000002027 skeletal muscle Anatomy 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000002110 toxicologic effect Effects 0.000 description 2
- 231100000027 toxicology Toxicity 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- 235000019786 weight gain Nutrition 0.000 description 2
- CFRFHWQYWJMEJN-UHFFFAOYSA-N 9h-fluoren-2-amine Chemical compound C1=CC=C2C3=CC=C(N)C=C3CC2=C1 CFRFHWQYWJMEJN-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 206010013183 Dislocation of vertebra Diseases 0.000 description 1
- IWDQPCIQCXRBQP-UHFFFAOYSA-M Fenaminosulf Chemical compound [Na+].CN(C)C1=CC=C(N=NS([O-])(=O)=O)C=C1 IWDQPCIQCXRBQP-UHFFFAOYSA-M 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000019280 Pancreatic lipases Human genes 0.000 description 1
- 108050006759 Pancreatic lipases Proteins 0.000 description 1
- 241001529469 Phoca groenlandica Species 0.000 description 1
- 101000800134 Rattus norvegicus Thyroglobulin Proteins 0.000 description 1
- 241000607768 Shigella Species 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 241000282894 Sus scrofa domesticus Species 0.000 description 1
- 206010050208 Teratospermia Diseases 0.000 description 1
- 208000002312 Teratozoospermia Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 210000003459 common hepatic duct Anatomy 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003544 deproteinization Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 210000000918 epididymis Anatomy 0.000 description 1
- 201000010063 epididymitis Diseases 0.000 description 1
- 201000005577 familial hyperlipidemia Diseases 0.000 description 1
- 235000021050 feed intake Nutrition 0.000 description 1
- 210000001105 femoral artery Anatomy 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000007674 genetic toxicity Effects 0.000 description 1
- 231100000025 genetic toxicology Toxicity 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 210000003701 histiocyte Anatomy 0.000 description 1
- 230000003118 histopathologic effect Effects 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000000055 hyoplipidemic effect Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000002262 irrigation Effects 0.000 description 1
- 238000003973 irrigation Methods 0.000 description 1
- -1 lipid peroxide Chemical class 0.000 description 1
- 239000002932 luster Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000010461 other edible oil Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229940116369 pancreatic lipase Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000011076 safety test Methods 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 230000021595 spermatogenesis Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
项目 | 指标 |
水分及挥发物,% ≤ | 0.2 |
酸价,mg KOH/g ≤ | 2.0 |
过氧化值,meq/Kg ≤ | 6.0 |
杂质,% ≤ | 0.1 |
项目 | 指标 |
净含量,g/粒 | 0.5 |
净含量允许负偏差,% ≤ | 9.0 |
水分及挥发物,% ≤ | 1.0 |
崩解时限,min ≤ | 60.0 |
酸价,mg KOH/g ≤ | 2.0 |
过氧化值,meq/Kg ≤ | 15.0 |
维生素E,mg/100g ≥ | 800 |
砷(以As计),mg/Kg ≤ | 1.0 |
铅(以pb计),mg/Kg ≤ | 1.5 |
汞(以Hg计),mg.Kg ≤ | 0.3 |
项目 | 指标 |
菌落总数,cfu/g ≤ | 1000 |
大肠菌群,MPN/100g ≤ | 40 |
霉菌计数,cfu/g ≤ | 10 |
酵母计数,cfu/g ≤ | 10 |
致病菌 | 不得检出 |
注:致病菌系指沙门菌、志贺氏菌、金黄色葡萄球菌、溶血性链球菌 |
项目 | 指标 |
二十二碳六烯酸(DHA),g/100g ≥ | 7.29 |
二十碳五烯酸(EPA),g/100g ≥ | 5.96 |
二十二碳五烯酸(DPA),g/100g ≥ | 3.55 |
剂量组(g/kg.bw) | 雄性 | 雌性 | ||
实验动物数 | 死亡动物数 | 实验动物数 | 死亡动物数 | |
21.5010.004.642.15 | 5555 | 0000 | 5555 | 0000 |
剂量(mg/皿) | TA97 | TA98 | TA100 | TA102 | ||||
-S9 | +S9 | -S9 | +S9 | -S9 | +S9 | -S9 | +S9 | |
5.0002.5001.2500.6250.313空白对照溶剂对照阴性对照阳性对照 | 135.7±15.0131.3±25.4141.7±37.0124.0±28.5119.0±23.6127.7±28.4141.7±28.9122.7±15.82037.7±78.9 | 124.0±20.8109.3±22.9126.3±27.8128.3±8.7126.0±45.9117.3±28.7140.0±27.2148.0±30.31162.7±162.1 | 41.0±1.737.7±9.940.0±7.040.7±3.241.3±8.346.0±3.647.0±2.638.0±7.2909.0±60.8 | 37.3±11.039.7±5.134.0±1.045.0±4.441.7±8.437.3±6.735.7±1.536.7±7.62482.7±204.1 | 170.3±37.6160.3±27.3135.0±30.9126.3±28.4144.0±26.9144.3±48.0170.0±34.8159.7±32.31763.3±40.3 | 120.0±11.1164.7±40.5176.0±13.2160.7±14.6149.0±2.6153.0±44.5141.3±32.1169.0±20.02479.3±215.1 | 286.7±13.6292.7±18.2285.3±31.2281.3±29.7293.0±27.0301.7±10.5285.7±26.1255.3±7.1895.0±3.0 | 293.7±28.1314.0±5.6286.3±22.4279.7±4.0295.7±22.5279.7±17.0279.7±30.0287.0±40.1267.3±13.5 |
剂量(mg/皿) | TA97 | TA98 | TA100 | TA102 | ||||
-S9 | +S9 | -S9 | +S9 | -S9 | +S9 | -S9 | +S9 | |
5.0002.5001.2500.6250.313空白对照溶剂对照阴性对照阳性对照 | 146.0±24.0152.0±12.8123.0±28.8142.7±13.1139.3±33.4150.0±26.5114.3±27.7133.7±37.22088.3±92.5 | 132.0±41.6161.8±31.8159.6±22.2152.3±31.1142.4±26.1154.5±40.4134.2±27.1141.3±40.51414.3±168.3 | 35.0±4.644.7±5.142.3±2.546.7±1.539.3±8.538.3±7.044.7±5.938.3±2.3913.3±29.2 | 39.7±9.034.0±2.040.3±9.042.0±6.133.7±1.535.3±4.541.0±7.044.0±4.42492.3±423.4 | 137.3±46.5136.0±25.2162.0±10.5152.3±21.5129.0±26.2139.0±46.0128.3±1.2153.7±20.82071.3±122.8 | 160.7±45.4169.7±49.9177.3±20.7128.7±18.1157.3±45.8165.0±18.5107.7±3.2162.0±13.72803.3±406.4 | 260.0±26.0299.3±13.0284.7±24.9301.3±14.4285.3±24.0274.3±37.9267.6±22.0281.3±16.5822.0±21.9 | 264.7±20.5303.7±17.2279.3±17.4287.7±26.6254.3±4.9288.7±18.7272.3±25.8272.0±24.1277.3±6.4 |
性别 | 剂量组(g/kg.bw) | 动物数(只) | 检查PCE数(个) | 含微核PCE数(个) | 微核数(‰) |
雄性 | 7.503.751.880.94阴性组阳性组 | 555555 | 5×10005×10005×10005×10005×10005×1000 | 78659124 | 1.41.61.21.01.824.8 |
雌性 | 7.503.751.880.94阴性组阳性组 | 555555 | 5×10005×10005×10005×10005×10005×1000 | 56796111 | 1.01.21.41.81.222.2 |
剂量组(g/kg.bw) | 动物数(只) | 观察精子数(个) | 精子畸形类型 | 畸形精子数(个) | 畸形率(‰) | |||||||
无定形 | 无钩 | 胖头 | 香蕉形 | 双头 | 双尾 | 尾折叠 | 其它 | |||||
7.503.751.88阴性对照组溶剂对照组阳性对照组 | 555555 | 5×10005×10005×10005×10005×10005×1000 | 6144515445163 | 2335233129132 | 1925262125123 | 2117261815112 | 000000 | 000000 | 1111236 | 000000 | 125122126125116566 | 25.024.425.225.023.2113.2 |
剂量组 | 动物数(只) | 始重(g) | 第1周体重(g) | 第2周体重(g) | 第3周体重(g) | 第4周体重(g) | |
雄 | ABCD | 10101010 | 65.0±3.862.1±4.164.2±5.662.4±4.1 | 91.6±7.492.3±9.598.4±9.393.5±5.7 | 128.1±15.6124.6±16.8135.6±9.6129.1±14.1 | 173.5±15.1169.8±15.6177.1±19.3176.7±14.1 | 206.9±18.8209.7±17.1217.9±18.3215.4±14.5 |
雌 | A | 10 | 60.8±4.9 | 86.8±7.4 | 132.0±9.5 | 165.7±6.5 | 193.2±9.9 |
BCD | 101010 | 62.7±4.661.3±4.660.5±4.2 | 90.7±6.684.0±5.088.7±8.8 | 133.9±10.0127.9±12.1125.1±11.3 | 166.4±13.1161.6±18.5156.0±10.3 | 193.0±16.2190.0±20.5182.2±14.6 |
性别 | 剂量组 | 动物数(只) | 体重增重(g) | 进食量(g) | 食物利用率(%) |
雄 | ABCD | 10101010 | 141.9±17.3147.5±14.9153.8±14.9153.0±12.9 | 516.9±55.0512.5±57.2548.3±47.7533.8±46.9 | 27.528.828.128.7 |
雌 | ABCD | 10101010 | 132.5±11.5130.4±16.0128.7±19.1121.7±14.3 | 502.4±25.4513.1±46.4487.4±47.6476.1±34.9 | 26.425.426.325.5 |
性别 | 剂量组 | 动物数(只) | 血红蛋白(g/dL) | 红细胞计数(×1012/L) | 白细胞计数(×109/L) |
雄 | ABCD | 10101010 | 15±414±313±313±4 | 9.89±1.449.96±1.4010.46±1.1210.29±1.12 | 8.8±1.08.9±1.19.6±1.09.6±1.0 |
雌 | ABCD | 10101010 | 12±214±313±313±3 | 10.60±1.0210.29±1.029.89±1.239.67±1.17 | 8.9±1.39.1±0.89.8±1.09.8±1.1 |
性别 | 剂量组 | 动物数(只) | GPT(U/L) | BUN(mmol/L) | GOT(U/L) | CR(μmol/L) | GLU(mmol/L) | TP(g/dL) | AIB(g/L) | CHO(mmol/L) | TG(mmol/L) |
雄 | ABCD | 10101010 | 80±1282±1573±1481±12 | 6.328±0.8336.578±0.8536.364±0.7576.041±0.971 | 204±29197±19307±55309±15 | 116.4±13.0105.5±14.4120.6±14.3119.2±10.4 | 9.30±1.058.53±1.459.41±2.288.35±1.62 | 10.5±0.611.0±0.810.6±0.510.9±0.8 | 45.9±4.445.1±2.150.8±3.045.6±1.9 | 2.62±0.432.49±0.312.65±0.392.48±0.45 | 0.99±0.191.10±0.380.93±0.190.97±0.23 |
雌 | ABCD | 10101010 | 73±1462±980±1184±14 | 6.386±0.6586.558±0.7816.309±0.8066.575±0.919 | 215±53213±33227±55222±80 | 116.4±11.5111.9±16.5121.9±16.1114.4±12.2 | 8.14±1.658.63±0.678.92±1.358.00±1.39 | 10.5±0.610.6±0.610.5±0.510.8±0.6 | 47.5±3.243.9±1.947.8±4.444.8±3.3 | 2.68±0.402.80±0.552.59±0.322.74±0.24 | 1.00±0.241.07±0.460.90±0.250.97±0.25 |
性别 | 剂量组 | 动物数(只) | 肝/体(%) | 脾/体(%) | 肾/体(%) |
雄 | ABCD | 10101010 | 3.713.743.913.57 | 0.230.230.260.22 | 0.790.770.760.75 |
雌 | ABCD | 10101010 | 3.653.663.613.76 | 0.270.230.230.22 | 0.800.830.760.81 |
剂量(mg/kg.bw) | 动物数(只) | 试验前体重(g) | 试验末期体重(g) | 试验末期增重(g) | P值 |
333331000空白对照溶剂对照高脂对照 | 101010101010 | 165.1±8.2163.0±8.0166.7±9.7166.1±10.3165.2±10.8164.1±11.0 | 317.3±28.7311.2±27.4314.3±25.1280.4±32.2286.6±27.7324.7±36.6 | 152.2±26.8148.2±33.1147.7±24.1114.3±28.3121.5±29.1160.7±36.7 | 0.54200.41760.33500.00290.0110-- |
剂量(mg/kg.bw) | 动物数(只) | 试验前 | 试验中期 | 试验末期 | |||
X±S | P值 | X±S | P值 | X±S | P值 | ||
333331000空白对照溶剂对照高脂对照 | 101010101010 | 1.83±0.201.92±0.261.91±0.251.93±0.141.96±0.131.97±0.17 | 0.12400.55100.48500.48300.8660---- | 2.07±0.252.07±0.212.05±0.251.97±0.101.96±0.102.11±.010 | 0.62500.62500.41400.00390.0018---- | 2.46±0.412.39±0.322.38±0.412.02±0.112.03±0.132.69±0.41 | 0.11800.04530.03530.00000.0000---- |
剂量(mg/kg.bw) | 动物数(只) | 试验中期 | 试验末期 | ||
X±S | P值 | X±S | P值 | ||
333331000空白对照溶剂对照高脂对照 | 101010101010 | 1.48±0.391.51±0.431.26±0.280.99±0.281.50±0.321.50±0.56 | 0.89500.99500.16400.00540.0021---- | 1.53±0.310.35±0.331.26±0.251.06±0.241.08±0.261.69±0.59 | 0.31200.03570.00780.00020.0002---- |
剂量(mg/kg.bw) | 动物数(只) | 试验中期 | 试验末期 | ||
X±S | P值 | X±S | P值 | ||
33 | 10 | 1.18±0.25 | 0.9710 | 1.17±0.23 | 0.9080 |
3331000空白对照溶剂对照高脂对照 | 1010101010 | 1.16±0.171.14±0.280.94±0.261.12±0.171.18±0.26 | 0.92100.75900.01670.5650---- | 1.13±0.141.16±0.170.93±0.211.09±0.161.16±0.23 | 0.75500.93500.01640.4790---- |
批号 | 20010520 | 20010601 | 20010610 |
第0个月稳定性试验 | |||
菌落总数,cfu/g大肠菌群,MPN/100g致病菌霉菌计数,cfu/g酵母菌计数,cfu/g二十碳五烯酸,%二十二碳六烯酸,%二十二碳五烯酸,%酸价过氧化值,meq/kg维生素E,mg/100g铅,mg/kg砷,mg/kg汞,mg/kg水分及挥发物,% | <10<30未检出<10<106.247.563.741.2610.28851<0.12<0.1<0.0030.07 | <10<30未检出<10<106.087.293.821.2810.25837<0.12<0.1<0.0030.12 | <10<30未检出<10<105.967.363.771.2610.26838<0.12<0.1<0.0030.09 |
第1个月稳定性试验 保存条件:相对湿度75% 温度37℃ | |||
菌落总数,cfu/g | <10 | <10 | <10 |
大肠菌群,MPN/100g致病菌霉菌计数cfu/g酵母菌计数,cfu/g二十碳五烯酸,%二十二碳六烯酸,%二十二碳五烯酸,%酸价过氧化值,meq/kg维生素E,mg/100g铅,mg/kg砷,mg/kg汞,mg/kg水分及挥发物,% | <30未检出<10<106.277.633.821.2810.30840<0.12<0.1<0.0030.09 | <30未检出<10<106.027.363.941.2810.26828<0.12<0.1<0.0030.11 | <30未检出<10<106.207.703.641.2610.38830<0.12<0.1<0.0030.10 | |
第2个月稳定性试验 保存条件:相对湿度75% 温度37℃ | ||||
菌落总数,cfu/g大肠菌群,MPN/100g致病菌霉菌计数,cfu/g酵母菌计数,cfu/g二十碳五烯酸,%二十二碳六烯酸,%二十二碳五烯酸,%酸价过氧化值,meq/kg维生素E,mg/100g铅,mg/kg砷,mg/kg汞,mg/kg水分及挥发物,% | <10<30未检出<10<106.367.543.721.2810.38836<0.12<0.1<0.0030.09 | <10<30未检出<10<106.197.673.621.2710.28831<0.12<0.1<0.0030.13 | <10<30未检出<10<106.117.823.551.2710.36834<0.12<0.1<0.0030.11 | |
第3个月稳定性试验 保存条件:相对湿度75% 温度37℃ | ||||
菌落总数,cfu/g大肠菌群,MPN/100g致病菌霉菌计数,cfu/g酵母菌计数,cfu/g二十碳五烯酸,%二十二碳六烯酸,%二十二碳五烯酸,% | <10<30未检出<10<106.497.683.82 | <10<30未检出<10<106.257.523.94 | 30<30未检出<10<106.157.323.64 |
酸价过氧化值,meq/kg维生素E,mg/100g铅,mg/kg砷,mg/kg汞,mg/kg水分及挥发物,% | 1.3010.43819<0.12<0.1<0.0030.10 | 1.3210.32835<0.12<0.1<0.0030.13 | 1.2810.46834<0.12<0.1<0.0030.12 |
Claims (1)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB031007546A CN1256950C (zh) | 2003-01-21 | 2003-01-21 | 海狗油软胶囊在制备调节血脂保健品中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB031007546A CN1256950C (zh) | 2003-01-21 | 2003-01-21 | 海狗油软胶囊在制备调节血脂保健品中的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1518989A CN1518989A (zh) | 2004-08-11 |
CN1256950C true CN1256950C (zh) | 2006-05-24 |
Family
ID=34281300
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB031007546A Expired - Fee Related CN1256950C (zh) | 2003-01-21 | 2003-01-21 | 海狗油软胶囊在制备调节血脂保健品中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1256950C (zh) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103800435B (zh) * | 2014-02-12 | 2015-02-25 | 山东天地健生物工程有限公司 | 一种海狗油软胶囊 |
CN104068402A (zh) * | 2014-06-29 | 2014-10-01 | 宁波市成大机械研究所 | 一种含有γ-亚麻酸的海狗油软胶囊 |
CN104082741A (zh) * | 2014-06-29 | 2014-10-08 | 宁波市成大机械研究所 | 一种含有虾青素的海狗油软胶囊 |
CN104082752A (zh) * | 2014-06-29 | 2014-10-08 | 宁波市成大机械研究所 | 一种含有角鲨烯的海狗油软胶囊 |
CN104172151A (zh) * | 2014-06-29 | 2014-12-03 | 宁波市成大机械研究所 | 一种含有辅酶q10的海狗油软胶囊 |
CN104187676A (zh) * | 2014-09-07 | 2014-12-10 | 宁波市成大机械研究所 | 含有葛根提取物的海狗油软胶囊 |
CN104256585A (zh) * | 2014-09-07 | 2015-01-07 | 宁波市成大机械研究所 | 含有核桃油的海狗油软胶囊 |
CN104187675A (zh) * | 2014-09-07 | 2014-12-10 | 宁波市成大机械研究所 | 含有银杏叶油的海狗油软胶囊 |
CN104187726A (zh) * | 2014-09-07 | 2014-12-10 | 宁波市成大机械研究所 | 含有罗布麻提取物的海狗油软胶囊 |
CN104187674A (zh) * | 2014-09-07 | 2014-12-10 | 宁波市成大机械研究所 | 含有银杏叶提取物的海狗油软胶囊 |
CN104187728A (zh) * | 2014-09-07 | 2014-12-10 | 宁波市成大机械研究所 | 含有核桃仁提取物的海狗油软胶囊 |
CN104187727A (zh) * | 2014-09-07 | 2014-12-10 | 宁波市成大机械研究所 | 含有丹参提取物的海狗油软胶囊 |
CN104544104A (zh) * | 2015-02-11 | 2015-04-29 | 昆明轿子雪山玛卡生物科技开发有限公司 | 一种玛卡与海狗油复合软胶囊 |
-
2003
- 2003-01-21 CN CNB031007546A patent/CN1256950C/zh not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CN1518989A (zh) | 2004-08-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0996740B1 (en) | Dha-containing nutritional compositions and methods for their production | |
CN1256950C (zh) | 海狗油软胶囊在制备调节血脂保健品中的应用 | |
US8343753B2 (en) | Compositions, methods, and kits for polyunsaturated fatty acids from microalgae | |
CN106793799B (zh) | 用于养殖动物的方法 | |
WO2007067207A1 (en) | Stabilized form of fish oil | |
CN1767769A (zh) | 油脂改良剂及含有油脂改良剂的组合物 | |
KR102287183B1 (ko) | 동애등에 공급을 통한 무지개송어 양식방법 및 사료조성물 | |
Gui et al. | Carotenoid-rich microalgae promote growth and health conditions of Artemia nauplii | |
PRIATNI et al. | Antidiabetic screening of some Indonesian marine cyanobacteria collection | |
JP4778792B2 (ja) | 動物プランクトン用飼料 | |
CN1167459C (zh) | 具有降血脂、延缓衰老功能的营养保健食品及其制备方法 | |
Nahavandi et al. | Investigation of the effect of diet containing Red algae (Laurencia caspica) on blood parameters and activity of digestive enzymes of goldfish (Carassius auratus) | |
CN102551041A (zh) | 一种精制海狗油、软胶囊及其在改善化学性肝损伤保健品中的应用 | |
EP0519916B1 (en) | Process for enrichment of fat with regard to polyunsaturated fatty acids and phospholipids, and application of such enriched fat | |
Yuslan et al. | Effect of bio-organic fertilizer and agro-industrial residue on the growth and reproduction of cyclopoid copepod, Oithona rigida (Giesbrecht, 1896) | |
González-Meza et al. | Dietary supplementation effect of three microalgae on Penaeus vannamei growth, biochemical composition, and resistance to Vibrio parahaemolyticus (AHPND) | |
CN1256951C (zh) | 海狗油软胶囊在制备祛除黄褐斑的保健品中的应用 | |
CN1679626A (zh) | 海狗油及其组合物在制备防治化学性肝损伤保健品中的应用 | |
CN1072013C (zh) | 高含量α-亚麻酸的制剂的制备方法 | |
CN1255144C (zh) | 一种调节血脂的保健药物组合物及其制备方法 | |
CN1654640A (zh) | 超氧化物歧化酶组合物及其制备方法 | |
Ivan et al. | Analysis on the use of new ingredients in trout feed. | |
Sari et al. | Substitution of Fishmeal with Astaxanthin Chlorella vulgaris on growth, survival rate and feed efficiency of Tilapia (Oreochromis niloticus) | |
Pahl | The anti-obesity potential of Ulvan from the green seaweed Ulva | |
Noori et al. | Variation of chemical compositions and fatty acids profiles of Chlorella sp. utilizing physical shocks |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20151221 Address after: 250002, Shandong, Ji'nan Province Shun Shun Road No. 28, Shun Geng Village, Hong Shun court 4 Patentee after: Shandong sun tree Bioengineering Co., Ltd. Address before: 100026, room four, unit 8, South Building, middle Tuanjiehu Road, Beijing, Chaoyang District, Patentee before: Liu Wei Patentee before: Liu Junxiang Patentee before: He Weijian Patentee before: Liu Yun |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20160622 Address after: Ping Pingyin County of Ji'nan City, Shandong province 250400 Street No. 15 Patentee after: Shandong Inuit biological Polytron Technologies Inc Address before: 250002, Shandong, Ji'nan Province Shun Shun Road No. 28, Shun Geng Village, Hong Shun court 4 Patentee before: Shandong sun tree Bioengineering Co., Ltd. |
|
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20060524 Termination date: 20200121 |
|
CF01 | Termination of patent right due to non-payment of annual fee |